Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics.

The originator infliximab product, Remicade, was approved by the US Food and Drug Administration in August 1998 for the management of Chron's disease. Since this time, several infliximab biosimilar agents have entered the market to introduce competition and lower costs for patients as well as health care systems. Clinical trials comparing infliximab biosimilars with the originator product have consistently demonstrated noninferiority, along with similar adverse effect profiles, leading to the approval of 3 additional biosimilars: Renflexis (infliximab-abda), Avsola (infliximab-axxq), and Inflectra (infliximab-dyyb).

Enabling the Advanced Bioeconomy through Public Policy Supporting Biofoundries and Engineering Biology.

The bioeconomy concept is proliferating globally. However, the enabling roles of biotechnology may be getting sidelined in the strategies of some countries. A goal for engineering biology is alignment with the engineering design cycle to enable more rapid commercialization.

Medication Quantification Scale Version III: update in medication classes and revised detriment weights by survey of American Pain Society Physicians.

Unlabelled: The Medication Quantification Scale (MQS) is an instrument with potential clinical and research applications for quantifying medication regimen use in chronic pain populations. The MQS was developed in 1992 and updated in 1998 (MQS II) as a tool to co-quantify 3 relevant aspects of medications prescribed for chronic nonmalignant pain: drug class, dosage, and detriment (risk). This 2003 version (MQS III) is the third iteration of the scale, featuring new detriment weights determined by surveying all physician members of the American Pain Society in the United States via mail.

Stability of midazolam hydrochloride in a flavored, dye-free oral solution.

The stability of injectable midazolam hydrochloride in a solution for oral use was studied at three temperatures over 56 days. A 2.5-mg/mL oral solution was prepared from injectable midazolam hydrochloride and a flavored, dye-free syrup.

A comparison of ethanol partitioning in biological and model membranes: nonideal partitioning is enhanced in synaptosomal membranes.

The partitioning of ethanol into mouse brain synaptosomes at 37 degrees C was characterized as a function of ethanol concentration. In addition, the partitioning of ethanol into multilamellar dipalmitoylphosphatidylcholine (DPPC) vesicles was characterized as a function of ethanol concentration and temperature. DPPC liposomes provided a model for ethanol partitioning into a phospholipid bilayer of defined composition allowing comparison to the more complex synaptosomal membrane.